Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab-Reference-Cited by-同舟云学术

Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab

Published:2024-03-02 Issue:5 Volume:29 Page:612-619
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Hashimoto Masaki^ORCID,Fukuokaya Wataru,Yanagisawa Takafumi,Yamamoto Shutaro,Koike Yuhei,Imai Yu,Iwatani Kosuke,Onuma Hajime,Ito Kagenori,Urabe Fumihiko,Tsuzuki Shunsuke,Kimura Shoji,Oyama Yu,Abe HIrokazu,Miki Jun,Kimura Takahiro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02482-7.pdf

Reference33 articles.

1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026. https://doi.org/10.1056/NEJMoa1613683

3. Kobayashi T, Ito K, Kojima T et al (2021) Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 112:760–773. https://doi.org/10.1111/cas.14762

4. Vuky J, Balar AV, Castellano D et al (2020) Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 38:2658–2666. https://doi.org/10.1200/JCO.19.01213

5. Parikh RB, Galsky MD, Gyawali B et al (2019) Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice. Oncologist 24:e397–e399. https://doi.org/10.1634/theoncologist.2019-0039

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration;International Journal of Molecular Sciences;2024-05-01